This sterile eye drops is indicated for the treatment of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension who are insufficiently responsive to topical beta blockers.
Dorzolamide Hydrochloride and Timolol Maleate reduce intraocular pressure (IOP) by combined action. Dorzolamide is human carbonic anhydrase II inhibitor which decreases aqueous humor secretion by slowing the formation of bicarbonate ions with subsequent reduction in sodium and fluid transport. Timolol is a non-selective beta adrenergic receptor blocker that does not have significant intrinsic sympathomimetic, direct myocardial depressant, or local anesthetic (membrane stabilizing) activity. It lowers IOP by decreasing the formation of aqueous humor in the ciliary epithelium.
Instill one drop in the conjunctival sac of the affected eye(s) twice daily. Use in children : Safety and effectiveness in children below the age of 2 years have not been established. U se in elderly patients : No overall differences in safety and effectiveness have been observed between elderly and other adult patients.
Mild burning, ocular hyperemia, blurred vision may occur.
Always consult a registered doctor before taking any medicine. This information is for general knowledge only.
Contraindicated in patients who are hypersensitive to any of the components of this preparation.
Additive hypotension and bradycardia with oral calcium channel blockers, catecholamine-depleting drugs or β-blockers, antiarrhythmics (e.g. amiodarone), digitalis glycosides, parasympathomimetics, narcotics and MAOIs. Additive systemic side effects with oral carbonic anhydrase or β-blockers; avoid concurrent use. Additive systemic β-blockade with CYP2D6 inhibitors (e.g. quinidine, SSRIs) and timolol.
For ophthalmic use only. Patients should remove their contact lenses prior to instilling Cozopt and should not insert their lenses until 15 minutes after instillation of the preparation.